PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
Elena Castro, MD, PhD - Radioligand Therapy and Therapeutic Sequencing in mCRPC
Visit https://www.peervoice.com/AKT860 to view the entire programme with slides. After completing “Elena Castro, MD, PhD - Radioligand Therapy and Therapeutic Sequencing in mCRPC”, participants will be able to: Identify approved and emerging prostate-specific membrane antigen (PSMA) targeted radioligand therapies (RLTs) for patients with metastatic castration-resistant prostate cancer (mCRPC); Use patient and disease characteristics to select which patients with mCRPC may benefit most from PSMA-targeted RLT; Explain what factors can impact the place of RLT in the treatment sequence for patients with mCRPC; Recognise clinical trials that will help inform therapeutic sequencing in mCRPC; and Propose appropriate treatment for patients with mCRPC who progress on RLT.